Investigating how to turn off cancer-related enzymes to discover new drugs
Official title: Base-Editing the Cancer Kinome to Enable Drug Discovery
Funded at Columbia University Health Sciences · NIH-10687392 · Data updated 2026-11-12
This study is looking at how certain enzymes called kinases affect cancer cells, especially in breast cancer, by using new techniques to turn them off, which could help find better treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $1,480,500 |
| NIH project number | 1DP2CA290245-01 |
| Project ID | NIH-10687392 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with breast cancer or other malignancies that may benefit from targeted kinase therapies.
✕Less likely to help
Patients with non-malignant conditions or those whose cancers are not driven by kinase dysregulation may not receive benefit from this research.
What this research studies
This research focuses on understanding the role of kinase enzymes in cancer cell function by using advanced base editing techniques to selectively turn off these enzymes. By manipulating the activity of kinases, which are crucial for cell signaling and growth, the research aims to identify new therapeutic targets for cancer treatment. The approach allows for precise modifications across the entire kinome, potentially leading to the discovery of effective drug combinations for various cancers, particularly breast cancer. Patients may benefit from the insights gained into how these enzymes contribute to cancer progression and treatment resistance.
Why it matters
Potential benefit: If successful, this research could lead to the development of new targeted therapies for breast cancer and other malignancies.
How similar studies have gone: Previous research has shown promise in targeting kinases for cancer treatment, indicating that this approach could lead to significant advancements in oncology.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Vasan, Neil — Columbia University Health Sciences
- Study coordinator: Vasan, Neil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.